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Summary 
A  novel human CC chemokine complementary DNA was identified in a library constructed 
from human fetal RNA, cloned into a baculovirus vector, and expressed in Sf9 insect cells. The 
mature  recombinant  protein  that  was  released  had  the  NH2-terminal  sequence  pyro- 
QPDALNVPSTC...and consisted of 75 amino acids.  Minor amounts of two variants of 77 and 
82 residues  (NH2 termini:  LAQPDA...and  FNPQGLAQPDA...)  were released as well.  The 
novel chemokine was designated monocyte chemotactic protein 4  (MCP-4)  and the variants 
were designated (LA)MCP-4 and (FNPQGLA)MCP-4. MCP-4 shares the pyroglutamic acid- 
proline NH2-terminal motif and 56-61% sequence identity with the three known monocyte 
chemotactic proteins and is 60% identical to eotaxin.  It has marked functional similarities to 
MCP-3 and eotaxin. Like MCP-3, MCP-4 is a chemoattractant of high efficacy for monocytes 
and T  lymphocytes. On these cells,  it binds to receptors that recognize MCP-1,  MCP-3,  and 
RANTES.  On  eosinophils,  MCP-4  has similar efficacy and potency as MCP-3,  RANTES, 
and eotaxin. It shares receptors with eotaxin and shows full cross-desensitization with this eo- 
sinophil-selective chemokine. Of the two variants, only (LA)MCP-4 could be purified in suffi- 
cient quantities for testing and was found to be at least 30-fold less potent than MCP-4 itself. 
This suggests that the 75-residue form with the characteristic NH  2 terminus of an MCP is the 
biologically relevant species. 
T 
he  number  of chemokines  of the  CC  subfamily has 
grown considerably during the past few years, and im- 
portant new information has been gathered about their ac- 
tivities  on  different  types  of leukocytes  (1).  Of particular 
interest were the  findings  that  the  monocyte chemotactic 
proteins (MCPs) are not only effective on monocytes (2-4), 
but also attract CD4 + and CD8 + T  lymphocytes (5, 6) and 
basophil  leukocytes  (7-10).  MCP-3  (10)  and  R_ANTES 
(11)  were also shown to be powerful attractants of eosino- 
phil leukocytes and, most recently, eotaxin, a CC chemokine 
with marked sequence similarity to MCP-3,  was found to 
share this activity and to be unusually selective for eosino- 
phils (12-14). 
In a program aiming at the discovery of human genes by 
large-scale  sequencing  of partial  cDNA  clones,  a  novel 
chemokine  cDNA was identified  in  a  library constructed 
from  human  fetal  mRNA.  The  full-length  cDNA  was 
cloned into a baculovirus expression vector, and the chemo- 
kine obtained was designated CK[310. A  screening for the 
induction of changes of the cytosolic free Ca  2+ concentra- 
tion  ([Ca2+]i)  in  human  blood  monocytes  showed  that 
CK[310 was as effective as MCP-1  and MCP-3. We com- 
pared its biological activity on human monocytes, neutro- 
phils, eosinophils, and T  lymphocytes with that ofMCP-1, 
MCP-2,  MCP-3,  RANTES,  MIP-lc~,  and  eotaxin,  and 
found that CK[310 is functionally very similar to MCP-3. 
Since the novel CC chemokine also shares marked sequence 
identity to the monocyte chemotactic proteins, we adopted 
the term MCP-4.  This designation is actually not new. A 
153-bp PCR fragment was previously cloned from human 
bone marrow mRNA and shown to encode a fragment of a 
novel CC chemokine (15).  On the basis  of the nucleotide 
sequence  similarity  with  MCP-1,  MCP-2,  and  MCP-3, 
the putative chemokine was termed MCP-4,  even though 
the protein was not expressed and no information about bi- 
ological activities could be obtained (15).  The sequence of 
the cloned fragment (Berger, M., personal communication) 
corresponds exactly to part of the CK[310 gene. 
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Cloning and Expression.  The coding sequence of MCP-4 was 
amplified by PCP, from a human fetal cDNA library (Human Ge- 
home  Sciences Inc., R.ockville, MD)  using the forward primer 
5'-CGCGGGATCCTTAACCTTCAACATGAAA and the re- 
verse primer 5'-CGCGGGTACCTTAACACATAGTACATTTT. 
The gene was dissected with BamHI and Asp718, inserted down- 
stream of the polyhedrin promoter into the vector pRG1, a mod- 
ification of pNR.704  (16),  and sequenced. The vector was trans- 
fected into  Sf9  insect  cells  (ATCC  CP,  L  1711)  together with 
linearized baculovirus DNA (BaculoGOLDTM;  Pharmingen, San 
Diego,  CA) using the lipofectin method,  rMCP-4  was  purified 
from the supernatant of serum-free St9 cell cultures in the pres- 
ence of protease inhibitors (20  btg/ml Pefabloc SC; Boehringer, 
Mannheim,  Germany,  1 I~g/ml leupeptin, 1 btg/ml E64,  and  1 
mM  EDTA)  by  three  chromatography steps:  cation exchange, 
heparin affinity, and size exclusion (poros 50 HS, poros 20 HE1, 
Perseptive Biosystem, and  Sephacryl $200  HP,;  Pharmacia Fine 
Chemicals, Piscataway, NJ).  The purified material was  analyzed 
by laser desorption mass spectrometry (matrix-associated laser de- 
sorption ionization-time of flight) and sequenced by Edman deg- 
radation. In addition, trypsin fragments were prepared (17), sepa- 
rated on reverse-phase HPLC, and peak fractions were analyzed 
by laser desorption mass spectroscopy. The material was further 
purified  by  chromatography  on  a  Minis  column  (Pharmacia) 
equilibrated  in  30%  CH3CN,  20  mM  potassium  phosphate, 
pH 6.0,  and eluted in a KC1 gradient. Peak fractions were sub- 
jected  to  reverse-phase chromatography on  a  ~P,  PC  C2/C18 
column (Pharmacia) and analyzed by laser desorption mass spec- 
trometry. 
Chemokine Standards.  The  chemokines used for comparison, 
MCP-1,  MCP-2,  MCP-3,  RANTES,  MIP-I~x,  and  eotaxin, 
were  chemically  synthesized  by  Dr.  I.  Clark-Lewis  (Hanson 
Centre for Cancer Research, Institute of Medical and Veterinary 
Science, Adelaide, Australia) according to  established protocols 
(18). 
Cells.  Monocytes  (4)  and  neutrophils  (19)  were  isolated at 
>90% purity from donor blood buffy coats supplied by the Cen- 
tral Laboratory of the Swiss Red Cross (Bern, Switzerland). The 
same source was used for the isolation of blood lymphocytes (5). 
Human CD4 + and CD8 + T  cell clones were maintained in cul- 
ture  and used according to Loetscher et al.  (5).  Fresh blood of 
healthy individuals was used to purify eosinophils by dextran sed- 
imentation  followed by  Percoll density-gradient centrifugation 
and  negative  selection with  anti-CD16  mAb-coated magnetic 
beads (11). 
In Vitro Chemotaxis.  Chemotaxis was assessed in 48-well cham- 
bers  (Neuro  Probe,  Cabin John,  MD)  using  polyvinylpyrroli- 
done-free polycarbonate membranes (Nucleopore Neuro Probe, 
Cabin John,  MD) with 5-1*m pores for monocytes and eosino- 
phils,  and  3-1*m  pores  for  lymphocytes.  RPMI  1640  supple- 
mented with 20 mM Hepes, pH 7.4, and 1% pasteurized plasma 
protein solution (the Central Laboratory of the Swiss R.ed Cross 
Laboratory) was  used  to  dissolve the  chemokines,  which  were 
placed in the lower well, and to suspend the cells (50,000 mono- 
cytes or eosinophils and  100,000  lymphocytes per upper well). 
After 60 min at 37~  the membrane was  removed, washed on 
the upper side with PBS, fixed, and stained. All assays were done 
in  triplicate, and  the  migrated cells  were  counted  in  five ran- 
domly selected fields  at  1,000-fold magnification.  Spontaneous 
migration was determined in the absence of chemoattractant. 
Enzyme Release.  The release of elastase was tested in neutro- 
phils  exactly  as  described  previously  (19).  The  release  of 
N-acetyl-J3-I)-glucosaminidase was  tested in  monocytes  (4).  In 
brief, samples of 1.2  X  106 monocytes in 0.3 ml prewarmed me- 
dium (136  mM NaC1,  4.8  mM KC1,  1.2 mM KH2PO  4,  1 mM 
CaC12, 20 mM Hepes, pH 7.4,  5 mM D-glucose, and  1 mg/ml 
fatty acid-free BSA) were pretreated for 2 min with cytochalasin 
B  (2.7  btg/ml) and stimulated with a chemokine.  The  reaction 
was  stopped after 3  min  by  cooling on  ice  and  centrifugation 
(6,000 g, 3 min), and enzyme activity was determined in the su- 
pernatant. 
Ca 2+ Changes.  Changes in the cytosolic free Ca  2+ concentra- 
tion ([Ca2+]i) were measured in monocytes, eosinophils, and lym- 
phocytes loaded with fura-2 by incubation for 30 min at 37~ 
with 0.2 nmol fura-2 acetoxymethylester per l06 cells in a buffer 
containing 136  mM  NaC1,  4.8  mM KC1,  1 m/Vl CaCl2,  5 mM 
glucose, and 20 mM Hepes, pH 7.4. After centrifugation, loaded 
cells were resuspended in the same buffer (106 cells/ml), stimu- 
lated with  the  indicated chemokine  at  37~  and  the  [Ca2+]i  - 
related fluorescence changes were recorded (20). 
Receptor Usage.  Receptor desensitization was tested in mono- 
cytes and  eosinophils by monitoring  [Ca2+]i changes  upon  re- 
peated  chemokine  stimulation  at  90-s  intervals  exactly as  de- 
scribed for monocytes by Uguccioni et al. (4). 
Results 
MCP-4 Expression and Analysis.  rMCP-4  that  was  re- 
leased into the culture supernatant of Sf9  cells was  readily 
purified by cation exchange,  heparin affinity, and  size ex- 
clusion chromatography  (see Materials and Methods).  On 
SDS-PAGE  (21),  the purified preparation yielded a  single 
band with a molecular mass of r  D  and no evidence 
for contaminant proteins. Laser desorption mass spectrome- 
try resolved a predominant peak and two very small peaks 
with masses of 8,575  -  30,  8,760  +  30,  and 9,314  +  30, 
respectively. Edman degradation of the mixture yielded two 
NH 2 termini, FNPQGLAQPDA  .  .  . and LAQPDA .... 
corresponding  to  the  two  minor  components.  No  se- 
quence was obtained for the major component.  The puri- 
fied material was  therefore  digested with  trypsin  and  the 
resulting peptides were separated by reverse-phase chroma- 
tography and analyzed. The largest fragments, which were 
derived from the NH 2 termini (Fig. 1), separated well from 
the smaller digestion peptides. Mass spectrometry of these 
fragments  revealed  a  major  sharp  peak  corresponding  to 
pyro-QPDALNVPSTCCFTFSSK  and  two  minor  peaks 
representing  LAQPDALNVPSTCCFTFSSK  and  FNP- 
QGLAQPDALNVPSTCCFTFSSK.  These results are con- 
sistent  with  the  sequencing  information,  since  pyro- 
glutamic  acid,  which  is  derived  from  deamidation  and 
cyclization  of the  NH2-terminal  glutamin,  is  resistant  to 
Edman  degradation.  The  term  MCP-4  was  attributed  to 
the major form (75 residues, tool wt  =  8,577)  and the mi- 
nor forms (77 and 82 residues, tool wt  =  8,779  and 9,324) 
were designated (LA)MCP-4 and (FNPQGLA) MCP-4. In 
Fig.  1,  the  sequences  of the  three  forms  are  aligned with 
those of MCP-3 and eotaxin, which share 60% amino acid 
identity  with  MCP-4.  The  identity  of  MCP-4  with 
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MCP-4  QPDALNVPSTCCFTFSSKKISLQRLKSYVITT.  SRCPQKAVIFRTKLGKEICADPKEKWVQNYMKHLGRKAHTLKT 
FNPQGLA"  CC .........  . --C ...............  C  ........ 
LA  CC  . --C'  'C  ........................ 
MCP-3  --VGT-TST-CCYR-  TN---PK---E--RR--S-HC-RS  ....  K---D---C---TQ  ....  DF ....  DK-TQ-P-T, 
Eotaxin  GPASV-T-CC-NLANR--P  .... S--RRI-SGKC  .......  K---A-D-C  .... K .... DS--Y-DQ-SP-P-P 
Figure 1.  Amino acid sequences of the three NH2-terminal variants of  MCP-4 aligned with MCP-3 and eotaxin. Identical amino acids are represented 
by hyphens. The cleavage site of trypsin yielding larger NH2-terminal fragments is indicated (arrowhead). 
RANTES,  MIP-lot,  and  MIP-li3  was  only  29,  39,  and 
41%, respectively. 
Enzyme Release in Monocytes.  MCP-4  and  (LA)MCP-4 
were isolated by reverse-phase chromatography for biolog- 
ical  testing,  but  (FNPQGLA)MCP-4  could  not  be  ob- 
tained in sufficient amounts. The activity was compared on 
monocytes, which respond readily to MCP-1, MCP-2, and 
MCP-3  (4),  by measuring the release of the lysosomal en- 
zyme N-acetyl-f3-D-glucosaminidase,  a test that is particu- 
larly reliable for a quantitative assessment. As shown in Fig. 
2  a,  MCP-4  induced  abundant release while  (LA)MCP-4 
was at least 30 times less potent.  In view of these  results, 
the  75-amino  acid  protein  with  NH  2  terminal  pyro- 
glutamic acid was used for further testing.  In Fig.  2  b, the 
effects of MCP-4  are  compared with  those  of other  CC 
chemokines.  The  response induced  by MCP-4  was  very 
similar to  that  observed with  MCP-2,  which  was  always 
somewhat less potent than MCP-1  and MCP-3. R_ANTES 
was markedly less active, and eotaxin was inactive. 
Chemotaxis.  MCP-4  induced  the  migration  of mono- 
cytes, eosinophils, and lymphocytes with a typical bimodal 
concentration dependence (Fig.  3).  The activity on mono- 
cytes was comparable to that of MCP-3, both in terms of 
efficacy and potency,  as indicated by the numbers  of mi- 
grating  cells  and  the  concentration  (100  nM)  at  which 
maximum  effects  were  observed.  In  agreement  with  a 
former study (4), MCP-1  was slightly more efficacious and 
considerably more potent as it reached its maximum activ- 
ity already at  1 nM.  In eosinophils, MCP-4  was tested in 
comparison with eotaxin and MCP-3, which are both po- 
tent attractants for these cells, while MCP-1  served as neg- 
ative control. MCP-4 and eotaxin elicited similar migration 
responses,  with  a  maximum  at  10-30  nM.  MCP-3  had 
comparable efficacy, but its maximum effective concentra- 
tion was 100 riM. MCP-4 also induced strong migration of 
CD4 + and CD8 + T lymphocytes. Its efficacy was similar to 
that of MCP-1,  but  10-100  nM MCP-4 was required for 
maximum effects, as compared to 1 nM MCP-1. Some mi- 
gration of both types ofT cells was also observed with eo- 
taxin at concentrations between 10 nM and 1 I~M. Freshly 
prepared blood lymphocytes did not migrate in response to 
any of the chemokines that were effective on cloned cells. 
lCa2+]i Changes.  A rapid and transient rise in [CaZ+]i was 
observed after MCP-4 stimulation of monocytes, lympho- 
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Figure  2.  Release of N-acetylq3-D-glucosaminidase from cytochalasin 
B-treated human blood monocytes in response to MCP-4 and other CC 
chemokines. Enzyme activity is presented in arbitrary fluorescence units. 
One out of" three similar experiments performed with cells from different 
donors is shown. 
Figure 3.  Chemotactic responses of human leukocytes to MCP-4 and 
other CC chemokines. Numbers of migrating cells per five high power 
fields,  rather  than  migration  index,  are  given  for  lymphocytes.  (,) 
MCP-4, (O) MCP-1, (~) MCP-3, (O) eotaxin. One out of three similar 
experiments performed with cells from different donors is shown. 
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Figure 4.  [Ca2+]i  changes in human CD4 + lymphocytes after stimula- 
tion with increasing concentrations of MCP-4 and MCP-1  (upper graphs), 
or 100 nM MIP-lct and eotaxin (lower  graphs). Arrows indicate the addi- 
tion of an agonist. Similar results were obtained with CD8 + lymphocytes. 
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cytes, and eosinophils. The  rate and magnitude  of the rise 
increased  with  the  concentration,  and  maximum  values 
were  obtained  at  chemokine  concentrations  between  10 
and 100 nM. MCP-4 and MCP-1  induced similar concen- 
tration-dependent [Ca2+]i transients in CD4 + and CD8 + T 
cells  (see  Fig.  4  for  data  on  CD4 +  cells).  Significant but 
much smaller changes were observed in both types of lym- 
phocytes after stimulation with MIP-loL and  eotaxin (Fig. 
4). The lower potency was expected since MIP-lot (5) and 
eotaxin (see above) are weak lymphocyte attractants. 
Desensitization  Experiments.  [Ca2+]i  changes after repeated 
stimulation were monitored in monocytes and eosinophils 
to assess receptor usage by MCP-4 and related chemokines. 
As shown in Fig. 5, stimulation ofmonocytes with MCP-1 
or MCP-3  abolished responsiveness to MCP-4,  indicating 
that the novel chemokine shares receptors with the mono- 
cyte  chemotactic  proteins.  The  response  to  MCP-4,  by 
contrast, was not affected by stimulation with R.ANTES or 
MIP-I~x. When  the monocytes were  first stimulated with 
MCP-4  MCP-1  MCP-J  MCP-4 
f  I  I  I 
0  O0 S  0  90 S 
Figure 5.  Cross-desensitization of human blood monocytes. Fura-2- 
loaded monocytes were stimulated sequentially at 90-s intervals with 50 
nM MCP-4 and other CC chemokines, and [Ca2+]i-dependent  fluores- 
cence changes were recorded. The tracings are representative for three to 
four separate experiments that were performed under identical conditions 
with cells from different donors. 
I  I  'I  i 
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Figure 6.  Cross-desensitization  of human blood eosinophils. The con- 
ditions are identical to those in Fig. 5.  Tracings are representative for 
three separate experiments that were performed with cells from different 
donors. 
MCP-4,  a  clear  decline  of  the  responses  to  MCP-1, 
RANTES,  and MIP-let,  as well as a  slight attenuation of 
the response to MCP-3, were observed. This desensitizing 
effect increased with the concentration of MCP-4 (data not 
shown). These results confirm that MCP-4 shares receptors 
with the MCPs, and indicate that it also recognizes a recep- 
tor that binds RANTES  and MIP-I~t. 
As illustrated in Fig. 6, marked cross-desensitization be- 
tween  MCP-4  and  MCP-3,  P,.ANTES,  and  eotaxin  was 
observed in eosinophils. MCP-4 appears to be a major ago- 
nist for these cells since it abrogated the response to a sub- 
sequent  stimulation with  eotaxin and MCP-3,  and  mark- 
edly decreased responsiveness to  RANTES.  These  results 
indicate  that  MCP-4  shares  the  receptors  with  MCP-3, 
P,.ANTES,  and eotaxin. Stimulation with MCP-4  did not 
affect  eosinophil responses  to  MIP-lot  (data  not  shown), 
indicating that this chemokine acts through a receptor that 
does not recognize MCP-4.  The same receptor is likely to 
bind  RANTES  because  some  activity of this  chemokine 
was  still  observed in  cells that  had  been  pretreated  with 
MCP-4. 
Actions on Neutrophils.  As a CC  chemokine with similarity 
to the MCPs, MCP-4 was not expected to activate neutro- 
phils. It was nevertheless tested in comparison with IL-8 as 
inducer of [Ca2+]i changes and elastase release and found to 
be  completely inactive in three independent  experiments, 
up to a concentration of 300 nM. 
Discussion 
Our  results  show  that  MCP-4  has  marked  functional 
similarities to MCP-3 and eotaxin. Like MCP-3, MCP-4 is 
a  chemoattractant  of high  efficacy but  relatively low  po- 
tency for monocytes and  T  lymphocytes. On  eosinophils, 
MCP-4  is  a  very powerful  attractant  matching  the  effec- 
tiveness  of eotaxin.  MCP-4  shares  receptors  mainly with 
MCP-3,  eotaxin, and RANTES,  as shown  particularly by 
cross-desensitization on eosinophils. 
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with  two  and  seven  additional  NH2-terminal  residues. 
(LA)MCP-4  had  only weak  activity  on  monocytes,  sug- 
gesting  that  (FNPQGLA)MCP-4,  which  could  not  be 
tested,  has little if any activity. It was formerly shown that 
addition  of alanine,  as  well  as  minor changes  at  the  NH2 
terminus  of MCP-1,  lead to major losses in biological ac- 
tivity (22).  Of particular interest is the finding that MCP-4 
has a pyroglutamic acid residue at the NH 2 terminus.  This 
also applies  to MCP-1,  MCP-2, and MCP-3, which were 
all reported to be NH z terminally blocked (2, 3), suggesting 
that pyroglutamic acid is the biologically relevant NH 2 ter- 
minus of all MCPs, 
On the basis  of sequence similarity,  CC chemokines can 
be  subdivided  into  two  groups,  one  including  MCP-1, 
MCP-2,  MCP-3,  and  eotaxin,  and  the  other  RANTES, 
MIP-I~x, and MIP-I[3. MCP-4, the novel CC chemokine 
described  in  this  paper,  clearly belongs  to  the  first  group 
since  it  shares  sequence  indentities  of 56-61%  with  the 
MCPs and eotaxin,  but only 29-41% with R_ANTES and 
the MIPs. In spite of the structural analogies,  there is con- 
siderable  functional  heterogeneity within  the  two  groups. 
Clear-cut differences in biological activity have been docu- 
mented for MCP-1  on one hand, and MCP-2 and MCP-3 
on the other (4,  10, 23). Eotaxin is even more distant, since 
it acts preferentially  on eosinophils  (12,  13),  quite in con- 
trast  to the  monocyte chemotactic proteins.  Some impor- 
tant dissimilarities in potency and target selectivity also exist 
among RANTES, MIP-Ioq and MIP-I[3 (1, 4, 5), and it is 
interesting  to  note  that  RANTES  shares  with  MCP-3 
some of the properties and receptor selectivities on eosino- 
phils and monocytes (4,  11). 
The present  results suggest that MCP-4 may be of par- 
ticular  importance  for its  activity  on  eosinophils.  In fact, 
while  MCP-4  was  somewhat  less  effective  than  MCP-1 
and MCP-3 in monocytes and lymphocytes, it was equiva- 
lent to eotaxin as an eosinophil attractant and was superior 
to MCP-3 in desensitizing these cells toward eotaxin. 
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